

Global Anti-IL-23 p19 Monoclonal Antibodies Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G1362CF160BDEN.html>

Date: July 2026

Pages: 87

Price: US\$ 3,480.00 (Single User License)

ID: G1362CF160BDEN

Abstracts

According to our (Global Info Research) latest study, the global Anti-IL-23 p19 Monoclonal Antibodies market size was valued at US\$ 24798 million in 2025 and is forecast to a readjusted size of US\$ 47898 million by 2032 with a CAGR of 8.3% during review period.

Anti-IL-23 p19 monoclonal antibodies are recombinant therapeutic biologics designed to selectively bind the p19 subunit of interleukin 23 and treat immune-mediated inflammatory diseases. The product scope mainly covers humanized or fully human IgG monoclonal antibody injections, including prefilled syringes, autoinjectors, subcutaneous formulations and intravenous induction formulations used in selected indications. Core manufacturing processes include antibody discovery and optimization, mammalian cell expression, cell culture, protein A purification, viral inactivation, ultrafiltration and concentration, aseptic filling, cold-chain release testing and biologics quality control. Key specifications include target-binding affinity, p19 selectivity, serum half-life, dosing interval, immunogenicity, formulation stability, purity, aggregate level, potency and batch-to-batch consistency. The main therapeutic function is to inhibit IL-23-mediated activation of the Th17 inflammatory pathway and reduce downstream cytokine activity, thereby improving chronic inflammatory diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. The industry is positioned within specialty biologics and autoimmune therapeutics, with demand driven by long-term treatment, expanded indications, improved dosing convenience and substitution from older immunology therapies. In 2025, mature commercialized anti-IL-23 p19 monoclonal antibody products generally achieved gross margins of about 80% to 90%.

Anti-IL-23 p19 monoclonal antibodies represent one of the most commercially established segments within specialty immunology biologics. The market is not characterized by a large number of manufacturers, but by a small group of approved therapies that have built strong positions through clear target selectivity, durable efficacy, convenient dosing and continuous indication expansion. The upstream chain includes cell line development, culture media, single-use bioreactors, purification resins, sterile filling materials and cold-chain systems. The midstream consists of antibody discovery, clinical development, regulatory registration, large-scale biologics manufacturing and quality release. The downstream market is concentrated in dermatology, rheumatology and gastroenterology, where chronic disease management and long treatment duration support resilient demand. Competition is highly concentrated, but the basis of competition is changing. Initial adoption was largely driven by plaque psoriasis, while future growth is increasingly linked to inflammatory bowel disease, psoriatic arthritis and broader immune-mediated conditions. New product launches and indication expansion remain the main commercial catalysts, but differentiation must be supported by sustained efficacy, safety, dosing convenience and real-world outcomes. Licensing, co-development and regional commercialization agreements are expected to remain active, particularly around late-stage pipelines and next-generation antibody formats. These transactions can improve development efficiency and accelerate geographic expansion, but they also make revenue attribution and market sizing more complex. The policy environment is broadly supportive of innovative biologics, especially where therapies address chronic inflammatory diseases with high unmet needs. At the same time, payer pressure, health technology assessment, price negotiation, biosimilar risk and patent-cycle dynamics will gradually moderate long-term growth. The industry remains a growth market, but it is moving from a rapid expansion phase toward a more mature phase driven by product differentiation and lifecycle management. Products with longer half-life, fewer injections, broader indication coverage and reliable manufacturing quality are likely to gain share, while late entrants with limited clinical or pricing advantages may face increasing commercialization pressure.

This report is a detailed and comprehensive analysis for global Anti-IL-23 p19 Monoclonal Antibodies market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Indication and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Anti-IL-23 p19 Monoclonal Antibodies market size and forecasts, in consumption value (\$ Million), sales quantity (Unit), and average selling prices (US\$/Unit), 2021-2032

Global Anti-IL-23 p19 Monoclonal Antibodies market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (Unit), and average selling prices (US\$/Unit), 2021-2032

Global Anti-IL-23 p19 Monoclonal Antibodies market size and forecasts, by Indication and by Application, in consumption value (\$ Million), sales quantity (Unit), and average selling prices (US\$/Unit), 2021-2032

Global Anti-IL-23 p19 Monoclonal Antibodies market shares of main players, shipments in revenue (\$ Million), sales quantity (Unit), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Anti-IL-23 p19 Monoclonal Antibodies

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Anti-IL-23 p19 Monoclonal Antibodies market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Innovent Biologics, Inc., Hansoh Pharmaceutical Group Company Limited, SUN Pharmaceuticals Industries Europe B.V., Industrias Farmac?uticas Almirall, S.A., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Anti-IL-23 p19 Monoclonal Antibodies market is split by Indication and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Indication, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Indication

Plaque Psoriasis

Psoriatic Arthritis

Crohn's Disease

Ulcerative Colitis

Others

Market segment by Molecule Type

Humanized IgG Monoclonal Antibodies

Fully Human IgG Monoclonal Antibodies

Fc-engineered or Long-acting Antibodies

Others

Market segment by Route of Administration

Subcutaneous Injection

Intravenous Induction plus Subcutaneous Maintenance

Intravenous Injection

Others

Market segment by Application

Hospitals

Specialist Clinics

Infusion Centers

Specialty Pharmacies

Retail and DTP Pharmacies

Others

Major players covered

AbbVie Inc.

Johnson & Johnson

Eli Lilly and Company

Sun Pharmaceutical Industries Limited

Innovent Biologics, Inc.

Hansoh Pharmaceutical Group Company Limited

SUN Pharmaceuticals Industries Europe B.V.

Industrias Farmac?uticas Almirall, S.A.

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Anti-IL-23 p19 Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Anti-IL-23 p19 Monoclonal Antibodies, with price, sales quantity, revenue, and global market share of Anti-IL-23 p19 Monoclonal Antibodies from 2021 to 2026.

Chapter 3, the Anti-IL-23 p19 Monoclonal Antibodies competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Anti-IL-23 p19 Monoclonal Antibodies breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Indication and by Application, with sales market share and growth rate by Indication, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Anti-IL-23 p19 Monoclonal Antibodies market forecast, by regions, by Indication, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-IL-23 p19 Monoclonal Antibodies.

Chapter 14 and 15, to describe Anti-IL-23 p19 Monoclonal Antibodies sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Indication

1.3.1 Overview: Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Indication: 2021 Versus 2025 Versus 2032

1.3.2 Plaque Psoriasis

1.3.3 Psoriatic Arthritis

1.3.4 Crohn's Disease

1.3.5 Ulcerative Colitis

1.3.6 Others

1.4 Market Analysis by Molecule Type

1.4.1 Overview: Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Molecule Type: 2021 Versus 2025 Versus 2032

1.4.2 Humanized IgG Monoclonal Antibodies

1.4.3 Fully Human IgG Monoclonal Antibodies

1.4.4 Fc-engineered or Long-acting Antibodies

1.4.5 Others

1.5 Market Analysis by Route of Administration

1.5.1 Overview: Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032

1.5.2 Subcutaneous Injection

1.5.3 Intravenous Induction plus Subcutaneous Maintenance

1.5.4 Intravenous Injection

1.5.5 Others

1.6 Market Analysis by Application

1.6.1 Overview: Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Application: 2021 Versus 2025 Versus 2032

1.6.2 Hospitals

1.6.3 Specialist Clinics

1.6.4 Infusion Centers

1.6.5 Specialty Pharmacies

1.6.6 Retail and DTP Pharmacies

1.6.7 Others

1.7 Global Anti-IL-23 p19 Monoclonal Antibodies Market Size & Forecast

1.7.1 Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021 & 2025)

& 2032)

1.7.2 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (2021-2032)

1.7.3 Global Anti-IL-23 p19 Monoclonal Antibodies Average Price (2021-2032)

2 MANUFACTURERS PROFILES

2.1 AbbVie Inc.

2.1.1 AbbVie Inc. Details

2.1.2 AbbVie Inc. Major Business

2.1.3 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.1.4 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 AbbVie Inc. Recent Developments/Updates

2.2 Johnson & Johnson

2.2.1 Johnson & Johnson Details

2.2.2 Johnson & Johnson Major Business

2.2.3 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.2.4 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.2.5 Johnson & Johnson Recent Developments/Updates

2.3 Eli Lilly and Company

2.3.1 Eli Lilly and Company Details

2.3.2 Eli Lilly and Company Major Business

2.3.3 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.3.4 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.3.5 Eli Lilly and Company Recent Developments/Updates

2.4 Sun Pharmaceutical Industries Limited

2.4.1 Sun Pharmaceutical Industries Limited Details

2.4.2 Sun Pharmaceutical Industries Limited Major Business

2.4.3 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.4.4 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.4.5 Sun Pharmaceutical Industries Limited Recent Developments/Updates

2.5 Innovent Biologics, Inc.

2.5.1 Innovent Biologics, Inc. Details

2.5.2 Innovent Biologics, Inc. Major Business

2.5.3 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.5.4 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.5.5 Innovent Biologics, Inc. Recent Developments/Updates

2.6 Hansoh Pharmaceutical Group Company Limited

2.6.1 Hansoh Pharmaceutical Group Company Limited Details

2.6.2 Hansoh Pharmaceutical Group Company Limited Major Business

2.6.3 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.6.4 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.6.5 Hansoh Pharmaceutical Group Company Limited Recent Developments/Updates

2.7 SUN Pharmaceuticals Industries Europe B.V.

2.7.1 SUN Pharmaceuticals Industries Europe B.V. Details

2.7.2 SUN Pharmaceuticals Industries Europe B.V. Major Business

2.7.3 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.7.4 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.7.5 SUN Pharmaceuticals Industries Europe B.V. Recent Developments/Updates

2.8 Industrias Farmac?uticas Almirall, S.A.

2.8.1 Industrias Farmac?uticas Almirall, S.A. Details

2.8.2 Industrias Farmac?uticas Almirall, S.A. Major Business

2.8.3 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

2.8.4 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.8.5 Industrias Farmac?uticas Almirall, S.A. Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: ANTI-IL-23 P19 MONOCLONAL ANTIBODIES BY MANUFACTURER

3.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Manufacturer (2021-2026)

3.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Manufacturer (2021-2026)

3.3 Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Manufacturer

(2021-2026)

3.4 Market Share Analysis (2025)

3.4.1 Producer Shipments of Anti-IL-23 p19 Monoclonal Antibodies by Manufacturer Revenue (\$MM) and Market Share (%): 2025

3.4.2 Top 3 Anti-IL-23 p19 Monoclonal Antibodies Manufacturer Market Share in 2025

3.4.3 Top 6 Anti-IL-23 p19 Monoclonal Antibodies Manufacturer Market Share in 2025

3.5 Anti-IL-23 p19 Monoclonal Antibodies Market: Overall Company Footprint Analysis

3.5.1 Anti-IL-23 p19 Monoclonal Antibodies Market: Region Footprint

3.5.2 Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Type Footprint

3.5.3 Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Anti-IL-23 p19 Monoclonal Antibodies Market Size by Region

4.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Region (2021-2032)

4.1.2 Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Region (2021-2032)

4.1.3 Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2021-2032)

4.2 North America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032)

4.3 Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032)

4.4 Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032)

4.5 South America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032)

4.6 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032)

5 MARKET SEGMENT BY INDICATION

5.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2032)

5.2 Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Indication (2021-2032)

5.3 Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication

(2021-2032)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application
(2021-2032)

6.2 Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Application
(2021-2032)

6.3 Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application
(2021-2032)

7 NORTH AMERICA

7.1 North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication
(2021-2032)

7.2 North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application
(2021-2032)

7.3 North America Anti-IL-23 p19 Monoclonal Antibodies Market Size by Country

7.3.1 North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country
(2021-2032)

7.3.2 North America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by
Country (2021-2032)

7.3.3 United States Market Size and Forecast (2021-2032)

7.3.4 Canada Market Size and Forecast (2021-2032)

7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

8.1 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication
(2021-2032)

8.2 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application
(2021-2032)

8.3 Europe Anti-IL-23 p19 Monoclonal Antibodies Market Size by Country

8.3.1 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country
(2021-2032)

8.3.2 Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country
(2021-2032)

8.3.3 Germany Market Size and Forecast (2021-2032)

8.3.4 France Market Size and Forecast (2021-2032)

8.3.5 United Kingdom Market Size and Forecast (2021-2032)

8.3.6 Russia Market Size and Forecast (2021-2032)

8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

9.1 Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2032)

9.2 Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2032)

9.3 Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Market Size by Region

9.3.1 Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Region (2021-2032)

9.3.2 Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Region (2021-2032)

9.3.3 China Market Size and Forecast (2021-2032)

9.3.4 Japan Market Size and Forecast (2021-2032)

9.3.5 South Korea Market Size and Forecast (2021-2032)

9.3.6 India Market Size and Forecast (2021-2032)

9.3.7 Southeast Asia Market Size and Forecast (2021-2032)

9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

10.1 South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2032)

10.2 South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2032)

10.3 South America Anti-IL-23 p19 Monoclonal Antibodies Market Size by Country

10.3.1 South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2021-2032)

10.3.2 South America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2021-2032)

10.3.3 Brazil Market Size and Forecast (2021-2032)

10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by

Indication (2021-2032)

11.2 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2032)

11.3 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Market Size by Country

11.3.1 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2021-2032)

11.3.2 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2021-2032)

11.3.3 Turkey Market Size and Forecast (2021-2032)

11.3.4 Egypt Market Size and Forecast (2021-2032)

11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)

11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

12.1 Anti-IL-23 p19 Monoclonal Antibodies Market Drivers

12.2 Anti-IL-23 p19 Monoclonal Antibodies Market Restraints

12.3 Anti-IL-23 p19 Monoclonal Antibodies Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Anti-IL-23 p19 Monoclonal Antibodies and Key Manufacturers

13.2 Manufacturing Costs Percentage of Anti-IL-23 p19 Monoclonal Antibodies

13.3 Anti-IL-23 p19 Monoclonal Antibodies Production Process

13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Anti-IL-23 p19 Monoclonal Antibodies Typical Distributors

14.3 Anti-IL-23 p19 Monoclonal Antibodies Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032

Table 2. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Molecule Type, (USD Million), 2021 & 2025 & 2032

Table 3. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032

Table 4. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. AbbVie Inc. Basic Information, Manufacturing Base and Competitors

Table 6. AbbVie Inc. Major Business

Table 7. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 8. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. AbbVie Inc. Recent Developments/Updates

Table 10. Johnson & Johnson Basic Information, Manufacturing Base and Competitors

Table 11. Johnson & Johnson Major Business

Table 12. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 13. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. Johnson & Johnson Recent Developments/Updates

Table 15. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors

Table 16. Eli Lilly and Company Major Business

Table 17. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 18. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Eli Lilly and Company Recent Developments/Updates

Table 20. Sun Pharmaceutical Industries Limited Basic Information, Manufacturing Base and Competitors

Table 21. Sun Pharmaceutical Industries Limited Major Business

Table 22. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 23. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 24. Sun Pharmaceutical Industries Limited Recent Developments/Updates

Table 25. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors

Table 26. Innovent Biologics, Inc. Major Business

Table 27. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 28. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 29. Innovent Biologics, Inc. Recent Developments/Updates

Table 30. Hansoh Pharmaceutical Group Company Limited Basic Information, Manufacturing Base and Competitors

Table 31. Hansoh Pharmaceutical Group Company Limited Major Business

Table 32. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 33. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 34. Hansoh Pharmaceutical Group Company Limited Recent Developments/Updates

Table 35. SUN Pharmaceuticals Industries Europe B.V. Basic Information, Manufacturing Base and Competitors

Table 36. SUN Pharmaceuticals Industries Europe B.V. Major Business

Table 37. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 38. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 39. SUN Pharmaceuticals Industries Europe B.V. Recent Developments/Updates

Table 40. Industrias Farmac?uticas Almirall, S.A. Basic Information, Manufacturing Base and Competitors

Table 41. Industrias Farmac?uticas Almirall, S.A. Major Business

Table 42. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product and Services

Table 43. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (Unit), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 44. Industrias Farmac?uticas Almirall, S.A. Recent Developments/Updates

Table 45. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Manufacturer (2021-2026) & (Unit)

Table 46. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Manufacturer (2021-2026) & (USD Million)

Table 47. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 48. Market Position of Manufacturers in Anti-IL-23 p19 Monoclonal Antibodies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 49. Head Office and Anti-IL-23 p19 Monoclonal Antibodies Production Site of Key Manufacturer

Table 50. Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Type Footprint

Table 51. Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Application Footprint

Table 52. Anti-IL-23 p19 Monoclonal Antibodies New Market Entrants and Barriers to Market Entry

Table 53. Anti-IL-23 p19 Monoclonal Antibodies Mergers, Acquisition, Agreements, and Collaborations

Table 54. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 55. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Region (2021-2026) & (Unit)

Table 56. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Region (2027-2032) & (Unit)

Table 57. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Region (2021-2026) & (USD Million)

Table 58. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Region (2027-2032) & (USD Million)

Table 59. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2021-2026) & (US\$/Unit)

Table 60. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2027-2032) & (US\$/Unit)

Table 61. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2026) & (Unit)

Table 62. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication

(2027-2032) & (Unit)

Table 63. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Indication (2021-2026) & (USD Million)

Table 64. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Indication (2027-2032) & (USD Million)

Table 65. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2026) & (US\$/Unit)

Table 66. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2027-2032) & (US\$/Unit)

Table 67. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2026) & (Unit)

Table 68. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2027-2032) & (Unit)

Table 69. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Application (2021-2026) & (USD Million)

Table 70. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Application (2027-2032) & (USD Million)

Table 71. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2026) & (US\$/Unit)

Table 72. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2027-2032) & (US\$/Unit)

Table 73. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2026) & (Unit)

Table 74. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2027-2032) & (Unit)

Table 75. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2026) & (Unit)

Table 76. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2027-2032) & (Unit)

Table 77. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2021-2026) & (Unit)

Table 78. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2027-2032) & (Unit)

Table 79. North America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2021-2026) & (USD Million)

Table 80. North America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2027-2032) & (USD Million)

Table 81. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2026) & (Unit)

Table 82. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2027-2032) & (Unit)

Table 83. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2026) & (Unit)

Table 84. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2027-2032) & (Unit)

Table 85. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2021-2026) & (Unit)

Table 86. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2027-2032) & (Unit)

Table 87. Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2021-2026) & (USD Million)

Table 88. Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2027-2032) & (USD Million)

Table 89. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2026) & (Unit)

Table 90. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2027-2032) & (Unit)

Table 91. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2026) & (Unit)

Table 92. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2027-2032) & (Unit)

Table 93. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Region (2021-2026) & (Unit)

Table 94. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Region (2027-2032) & (Unit)

Table 95. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Region (2021-2026) & (USD Million)

Table 96. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Region (2027-2032) & (USD Million)

Table 97. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2026) & (Unit)

Table 98. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2027-2032) & (Unit)

Table 99. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2026) & (Unit)

Table 100. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2027-2032) & (Unit)

Table 101. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by

Country (2021-2026) & (Unit)

Table 102. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2027-2032) & (Unit)

Table 103. South America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2021-2026) & (USD Million)

Table 104. South America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2027-2032) & (USD Million)

Table 105. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2021-2026) & (Unit)

Table 106. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Indication (2027-2032) & (Unit)

Table 107. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2021-2026) & (Unit)

Table 108. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Application (2027-2032) & (Unit)

Table 109. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2021-2026) & (Unit)

Table 110. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity by Country (2027-2032) & (Unit)

Table 111. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2021-2026) & (USD Million)

Table 112. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Country (2027-2032) & (USD Million)

Table 113. Anti-IL-23 p19 Monoclonal Antibodies Raw Material

Table 114. Key Manufacturers of Anti-IL-23 p19 Monoclonal Antibodies Raw Materials

Table 115. Anti-IL-23 p19 Monoclonal Antibodies Typical Distributors

Table 116. Anti-IL-23 p19 Monoclonal Antibodies Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Anti-IL-23 p19 Monoclonal Antibodies Picture
- Figure 2. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Indication, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Indication in 2025
- Figure 4. Plaque Psoriasis Examples
- Figure 5. Psoriatic Arthritis Examples
- Figure 6. Crohn's Disease Examples
- Figure 7. Ulcerative Colitis Examples
- Figure 8. Others Examples
- Figure 9. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Molecule Type, (USD Million), 2021 & 2025 & 2032
- Figure 10. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Molecule Type in 2025
- Figure 11. Humanized IgG Monoclonal Antibodies Examples
- Figure 12. Fully Human IgG Monoclonal Antibodies Examples
- Figure 13. Fc-engineered or Long-acting Antibodies Examples
- Figure 14. Others Examples
- Figure 15. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Route of Administration, (USD Million), 2021 & 2025 & 2032
- Figure 16. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Route of Administration in 2025
- Figure 17. Subcutaneous Injection Examples
- Figure 18. Intravenous Induction plus Subcutaneous Maintenance Examples
- Figure 19. Intravenous Injection Examples
- Figure 20. Others Examples
- Figure 21. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 22. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Application in 2025
- Figure 23. Hospitals Examples
- Figure 24. Specialist Clinics Examples
- Figure 25. Infusion Centers Examples
- Figure 26. Specialty Pharmacies Examples
- Figure 27. Retail and DTP Pharmacies Examples

Figure 28. Others Examples

Figure 29. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 30. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 31. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity (2021-2032) & (Unit)

Figure 32. Global Anti-IL-23 p19 Monoclonal Antibodies Price (2021-2032) & (US\$/Unit)

Figure 33. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Manufacturer in 2025

Figure 34. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Manufacturer in 2025

Figure 35. Producer Shipments of Anti-IL-23 p19 Monoclonal Antibodies by Manufacturer Sales (\$MM) and Market Share (%): 2025

Figure 36. Top 3 Anti-IL-23 p19 Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2025

Figure 37. Top 6 Anti-IL-23 p19 Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2025

Figure 38. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Region (2021-2032)

Figure 39. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value Market Share by Region (2021-2032)

Figure 40. North America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 41. Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 42. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 43. South America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 44. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 45. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Indication (2021-2032)

Figure 46. Global Anti-IL-23 p19 Monoclonal Antibodies Consumption Value Market Share by Indication (2021-2032)

Figure 47. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2032) & (US\$/Unit)

Figure 48. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by

Application (2021-2032)

Figure 49. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Application (2021-2032)

Figure 50. Global Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2032) & (US\$/Unit)

Figure 51. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Indication (2021-2032)

Figure 52. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Application (2021-2032)

Figure 53. North America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Country (2021-2032)

Figure 54. North America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value Market Share by Country (2021-2032)

Figure 55. United States Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 56. Canada Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 57. Mexico Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 58. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Indication (2021-2032)

Figure 59. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Application (2021-2032)

Figure 60. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Country (2021-2032)

Figure 61. Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption Value Market Share by Country (2021-2032)

Figure 62. Germany Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 63. France Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 64. United Kingdom Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 65. Russia Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 66. Italy Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 67. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Indication (2021-2032)

Figure 68. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Application (2021-2032)

Figure 69. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Region (2021-2032)

Figure 70. Asia-Pacific Anti-IL-23 p19 Monoclonal Antibodies Consumption Value Market Share by Region (2021-2032)

Figure 71. China Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 72. Japan Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 73. South Korea Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 74. India Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 75. Southeast Asia Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 76. Australia Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 77. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Indication (2021-2032)

Figure 78. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Application (2021-2032)

Figure 79. South America Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Country (2021-2032)

Figure 80. South America Anti-IL-23 p19 Monoclonal Antibodies Consumption Value Market Share by Country (2021-2032)

Figure 81. Brazil Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 82. Argentina Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 83. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Indication (2021-2032)

Figure 84. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Application (2021-2032)

Figure 85. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Quantity Market Share by Country (2021-2032)

Figure 86. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Consumption Value Market Share by Country (2021-2032)

Figure 87. Turkey Anti-IL-23 p19 Monoclonal Antibodies Consumption Value

(2021-2032) & (USD Million)

Figure 88. Egypt Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 89. Saudi Arabia Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 90. South Africa Anti-IL-23 p19 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

Figure 91. Anti-IL-23 p19 Monoclonal Antibodies Market Drivers

Figure 92. Anti-IL-23 p19 Monoclonal Antibodies Market Restraints

Figure 93. Anti-IL-23 p19 Monoclonal Antibodies Market Trends

Figure 94. Porters Five Forces Analysis

Figure 95. Manufacturing Cost Structure Analysis of Anti-IL-23 p19 Monoclonal Antibodies in 2025

Figure 96. Manufacturing Process Analysis of Anti-IL-23 p19 Monoclonal Antibodies

Figure 97. Anti-IL-23 p19 Monoclonal Antibodies Industrial Chain

Figure 98. Sales Channel: Direct to End-User vs Distributors

Figure 99. Direct Channel Pros & Cons

Figure 100. Indirect Channel Pros & Cons

Figure 101. Methodology

Figure 102. Research Process and Data Source

I would like to order

Product name: Global Anti-IL-23 p19 Monoclonal Antibodies Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G1362CF160BDEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1362CF160BDEN.html>